Skip to content

908 Devices MASS Free cash flow

Free cash flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$816M+126%
WAT
Waters CorporationWAT
-$42M-118%
Agilent Technologies logo
Agilent TechnologiesA
$201M+87.9%
Danaher logo
DanaherDHR
$1.09B+2.9%
Bruker logo
BrukerBRKR
Mettler-Toledo International, Inc. logo
Mettler-Toledo International, Inc.MTD

Other financials

Income statement

See full
Revenue$13.4M+13.6%
Gross profit$6.9M+24.2%
Operating income-$12.9M-16.9%
Net income-$12.0M-127%
EPS (diluted)-$0.32-126%

Balance sheet

See full
Cash & equivalents$67.6M-14.7%
Total debt$4.5M+18.6%
Total equity$134.2M-15.8%
Total assets$186.7M-4.8%

Cash flow

See full
Operating cash flow$1.2M+108%
CapEx$40.0K-74.8%

Valuation

See full
Market cap$339.57M+29.0%
Enterprise value$276.47M+47.2%
P/S5.9×+0.8×

Profitability

See full
Gross margin51.5%+1.3pp
Operating margin-76.8%-19.6pp
Net margin-62.4%+323pp
FCF margin-16.7%-7.2pp

Returns & leverage

See full
Return on equity-24.6%-149pp
Debt / equity0.0×
Current ratio3.6×-4.0×

Where this comes from

Calculated from 908 Devices’s reported figures.

The official record: 908 Devices’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about 908 Devices's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 908 Devices's free cash flow?
908 Devices (MASS) reported free cash flow of $1.17M in Q1 2026.
How has 908 Devices's free cash flow changed year-over-year?
908 Devices's free cash flow increased by 107.7% year-over-year, from -$15.18M to $1.17M.
What is the long-term trend for 908 Devices's free cash flow?
Over 4 years (2021 to 2025), 908 Devices's free cash flow has grown at a -3.4% compound annual growth rate (CAGR), from -$29.82M to -$25.97M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.